Lidocaine metabolism (WP2646)

Homo sapiens

Lidocaine is primarily metabolized by CYP1A2 but minor involvement of CYP3A4 is observed too. Based on [ KEGG]


Egon Willighagen and Kristina Hanspers


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens



Pathway Ontology

phase I biotransformation pathway via cytochrome P450 xenobiotic metabolic pathway


Label Type Compact Identifier Comment
2,6-xylidine Metabolite chebi:28738
3-hydroxymonoethylglycinexylidide Metabolite kegg.compound:C16572
glycinexylidide Metabolite chebi:357241
Lidocaine Metabolite hmdb:HMDB0014426
2-amino-3-methylbenzoate Metabolite pubchem.compound:4161142
monoethylglycinexylidide Metabolite pubchem.compound:24415
3-hydroxylidocaine Metabolite pubchem.compound:161824
4-hydroxy-2,6-dimethylaniline Metabolite chebi:55545
CYP3A4 GeneProduct ensembl:ENSG00000160868
CYP1A2 GeneProduct ensembl:ENSG00000140505
CYP1A2 GeneProduct ensembl:ENSG00000140505
CYP3A4 GeneProduct ensembl:ENSG00000160868


  1. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Wang JS, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT. Pharmacol Toxicol. 1999 Nov;85(5):201–5. PubMed Europe PMC Scholia
  2. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Clin Pharmacol Ther. 2004 Jan;75(1):80–8. PubMed Europe PMC Scholia
  3. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. Isohanni MH, Neuvonen PJ, Olkkola KT. Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):168–72. PubMed Europe PMC Scholia